The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer
Open accessAbstract
Even though cancer treatment has improved over the recent decades, still more specific and effective treatment concepts are mandatory. Surgical removal is not always possible, metastases are challenging and chemo- and radiotherapy can not only have severe side-effects but also resistances may occur. To cope with these challenges more efficient therapies with fewer side-effects are required. One promising approach is the use of drug delivery vehicles. Here, mesoporous silica nanoparticles (MSN) are discussed as biodegradable drug carrier to improve efficacy and reduce side-effects. MSN excellently fulfill the criteria for nanoparticulate carriers: their distinct structure allows high loading capacity and a plethora of surface modifications. MSN synthesis permits fine-tuning of particle and pore sizes. Moreover, drug release can be tailored through various gatekeeper systems which are for example pH-sensitive or redox-sensitive. Furthermore, MSN can either enter tumors passively by the enhanced permeability and retention effect or can be actively targeted by various ligands. PEGylation prolongs circulation time and availability. A huge advantage of MSN is their explicitly low toxic profile in vivo. Yet, clinical translation remains challenging. Overall, mesoporous silica nanoparticles are a promising tool for innovative, more efficient and safer cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Triblock Copolymer Syntheses of Mesoporous Silica with Periodic 50 to 300 Angstrom Pores
Zhao, D., Feng, J., Huo, Q., Melosh, N., Fredrickson, G. H., Chmelka, B. F., & Stucky, G. D. (1998) · Science · doi:10.1126/science.279.5350.548 · Cited by 11,753
Semiconductor Nanocrystals as Fluorescent Biological Labels
Bruchez, M., Moronne, M., Gin, P., Weiss, S., & Alivisatos, A. P. (1998) · Science · doi:10.1126/science.281.5385.2013 · Cited by 8,613
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Cited by
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
“MSNs [95] have the honeycomb-like porous structure of silica (SiO2), as shown in Fig.”
BackgroundLombardo, D., Kiselev, M. A., & Caccamo, M. T. (2019) · Journal of Nanomaterials · doi:10.1155/2019/3702518 · Cited by 864
Overcoming blood–brain barrier transport: Advances in nanoparticle-based drug delivery strategies
Ding, S., Khan, A. I., Cai, X., Song, Y., Lyu, Z., Du, D., Dutta, P., & Lin, Y. (2020) · Materials Today · doi:10.1016/j.mattod.2020.02.001 · Cited by 440
Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review
Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00002 · Cited by 370
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
Sultana, A., Zare, M., Thomas, V., Kumar, T. S. S., & Ramakrishna, S. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100134 · Cited by 315
Janjua, T. I., Cao, Y., Kleitz, F., Linden, M., Yu, C., & Popat, A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115115 · Cited by 259
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update
Castillo, R. R., Lozano, D., González, B., Manzano, M., Izquierdo-Barba, I., & Vallet-Regí, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598375 · Cited by 197
Toxicity of Carbon Nanotubes as Anti-Tumor Drug Carriers
Yan, H., Xue, Z., Xie, J., Dong, Y., Ma, Z., Sun, X., Kebebe Borga, D., Liu, Z., & Li, J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s220087 · Cited by 113
Kundu, M., Chatterjee, S., Ghosh, N., Manna, P., Das, J., & Sil, P. C. (2020) · Materials Science and Engineering: C · doi:10.1016/j.msec.2020.111239 · Cited by 89
AbouAitah, K., Swiderska-Sroda, A., Farghali, A. A., Wojnarowicz, J., Stefanek, A., Gierlotka, S., Opalinska, A., Allayeh, A. K., Ciach, T., & Lojkowski, W. (2018) · Oncotarget · doi:10.18632/oncotarget.25470 · Cited by 83
Shahein, S. A., Aboul-Enein, A. M., Higazy, I. M., Abou-Elella, F., Lojkowski, W., Ahmed, E. R., Mousa, S. A., & AbouAitah, K. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s206899 · Cited by 52
Lee, J. Y., Vyas, C. K., Kim, G. G., Choi, P. S., Hur, M. G., Yang, S. D., Kong, Y. B., Lee, E. J., & Park, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-43969-y · Cited by 47
Lee, C.-S., Kim, T., Oh, D., Bae, S., Ryu, J., Kong, H., Jeon, H., Seo, H., Jeon, S., & Kim, T. (2020) · Cancers · doi:10.3390/cancers12030634 · Cited by 46
Metadata
- Authors
- Watermann, A., & Brieger, J.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2017-07-22
- Volume
- 7
- Issue
- 7
- Pages
- 189
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W2739463248
- Cited by
- 404
- References
- 85
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.